BioCentury | Jul 2, 2020
Product Development

BioNTech, Pfizer vaccine yields highest titers to date, but benchmark itself remains an open question

BioNTech and Pfizer have unveiled early clinical data from the first of four COVID-19 vaccine candidates, becoming the first to disclose neutralizing antibody titers that surpass FDA’s recommended titer of 160 for convalescent plasma. Pfizer...
BioCentury | Jun 20, 2020

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BioCentury | Jun 19, 2020
Product Development

InflaRx, Kiniksa anti-inflammatory mAbs yield trend toward lower COVID-19 mortality, plus Sinopharm reports antibody readout from vaccine trial

After dexamethasone set a new bar for mortality reduction in COVID-19 patients this week, InflaRx and Kiniksa reported data from their anti-inflammatory mAbs showing trends toward a survival benefit. InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday...
BioCentury | Jun 16, 2020
Product Development

Sinovac COVID-19 vaccine yields neutralizing antibodies in Phase II, titers not revealed

Sinovac’s disclosure over the weekend of early clinical data from its COVID-19 vaccine makes it the third company to demonstrate production of neutralizing antibodies in humans, behind Moderna and CanSino. Sinovac’s data come from many...
BioCentury | Jun 13, 2020
Product Development

Moderna vaccine first to produce sterilizing immunity in model system -- though only in mice

The first detailed data from Moderna’s COVID-19 vaccine show mRNA-1273 induces neutralizing antibody titers in range of those from other leading candidates, at least in mice, and hint at sterilizing immunity. Despite the major caveat...
BioCentury | Jun 12, 2020
Product Development

AZ, BioNTech continue to build capacity to manufacture COVID-19 vaccines

Manufacturing deals for COVID-19 vaccine candidates continued to gain momentum Thursday, with two of the most advanced companies entering deals that will help them expand capacity to make their products. Emergent BioSolutions Inc. (NYSE:EBS) announced...
BioCentury | Jun 10, 2020
Product Development

Daily Chart: comparing neutralizing titers from four COVID-19 vaccines in non-human primates

At least four COVID-19 vaccine developers have reported neutralizing titers from immunized non-human primates, with Novavax’s NVX CoV2373 producing at least an order of magnitude higher titers than the other three. However, differing vaccination regimens...
BioCentury | Jun 10, 2020
Product Development

Novavax announces high neutralizing antibody titers in COVID-19 vaccine

A COVID-19 candidate vaccine from Novavax has produced the highest reported levels of neutralizing titers in non-human primate studies. “We are seeing neutralizing titers in the 10,000 range in non-human primates,” Gregory Glenn, president of...
BioCentury | Jun 6, 2020
Product Development

Multiple COVID-19 vaccines still in the running despite missing Warp Speed’s cut

Operation Warp Speed has designated COVID-19 vaccine candidates from five groups as the most likely to produce an effective product, but that doesn’t mean other developers are out of the race. The U.S. initiative seeks...
BioCentury | May 23, 2020
Product Development

Making sense of the deluge of early COVID-19 vaccine data

It’s been a big couple of weeks for COVID-19 vaccine data, and the findings are simultaneously encouraging and disheartening. While they hint that some level of protection is achievable -- by multiple candidates -- more...
Items per page:
1 - 10 of 129